Thinly traded micro cap CorMedix (CRMD +10.6%) is up on below-average volume in early trade in reaction to its announcement
that the FDA has agreed to a rolling review of its marketing
application seeking approval for Neutrolin for the prevention of
catheter-related bloodstream infections in hemodialysis patients.
The company continues to expect the FDA nod in H2.
https://seekingalpha.com/news/3537344-cormedix-up-11-on-accelerated-review-of-neutrolin-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.